Globally, the life sciences industry is emerging to grow leaps and bounds. The current demand on pharmaceuticals is over US $ 500 million worldwide. The R&D scenario too is witnessing a corresponding increase in spending with the rapidly expanding industry.

The emphasis on manufacturing triggers custom synthesis and outsourcing businesses. With more and more players worldover turning to India as a strategic hub to outsource manufacturing, research and synthesis, the country's importance as a potential destination in the global pharmaceutical arena increases.

In such a competitive scenario, the Indian pharmaceutical market has shown rapid growth over the years and has established itself in the global arena. Indian fine chemical and drug manufacturers are establishing themselves as participants to be reckoned with, say reports.
Frost & Sullivan's international conference on "Opportunities in Life Science Molecules: Global Partnership Summit," achieves tremendous significance in this context.

The three-day meet which is scheduled to be held at The Leela in Goa from 3rd to 5th June will explore the relevant and strategic issues of the growing symbiotic relationship between global and Indian fine chemical and drug manufacturers.

Decision makers and corporate heads of the leading pharmaceutical and fine chemical companies are expected to converge at the summit. The focus of the conference will be on recent developments in the global pharmaceuticals and active ingredients/intermediate industry in the key areas of R&D, strategic partnerships, manufacturing excellence & methodologies, and marketing strategies.

Delegates from Lonza Group Ltd, DSM Pharma Chemicals, Cambrex Corporation, LANXESS, Diosynth BV, Wyeth Pharmaceuticals, American Pharmaceutical Partners, and Alpharma will share their knowledge and address business issues on various topics in the first two days. These topics will cover relevant themes such as the opportunities that exist in outsourcing, technology licensing and contract research, critical factors considered for partner selection, opportunities for emerging technologies in drug manufacturing, and strategies for global leadership.
The conference will also include 2 specific workshops, facilitated by eminent speakers, addressing key issues of the pharmaceutical industry today